Hepion Pharmaceuticals, Inc. (CTRVP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Hepion Pharmaceuticals, Inc. (CTRVP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On August 19, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) approved the appointment of Jam
How this was made
The 30-second read
Why it matters
The filing provides the first public notice of the new director; impact on share price is expected to be negligible.
Market read
Routine corporate governance update with low trading relevance.
What to watch
Potential future board dynamics, but no immediate material effect.
Background
SEC Form 8‑K reporting a director appointment for Hepion Pharmaceuticals (CTRVP).
Ticker impact
Board appointed James Liddy as a director on August 19, 2026, disclosed in an 8‑K filing.
minimal
Director appointments are routine corporate actions with limited trading relevance.
Market effects
none
none
none
Counterpoint
No contrarian angle; the filing is routine.
Key entities
- companyHepion Pharmaceuticals, Inc.
Biopharma company filing the 8‑K.
- personJames Liddy
Appointed as a director.
